Cinclus: Positive read-x, PCABs are growing in the US
We are encouraged to see that since its launch on the US market, PCABs have seen steady market penetration, as highlighted by Phathom Pharma's Q3'24 on vonoprazan (1st gen. PCAB) (+30% beat vs css on sales), which highlighted i) a strong growth in filled prescriptions, which amounted 69,000 (+97% Q
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.